Answers are grounded in this paper and cite their sources.
Cross-sectional study reveals systemic immune activation in cancer-free individuals with hereditary cancer syndromes, suggesting potential targets for future risk-reduction strategies.
Background Immune surveillance mechanisms contribute to the elimination of precancerous lesions in hereditary cancer predisposition syndromes (HCPSs). Methods By combining single-cell transcriptomics, multiparametric mass cytometry and cytokine profiling of the systemic immune environment in 391 individuals among whom 227 are living with HCPSs we investigated phenotypic alterations in cancer-free individuals with HCPS. Results A decrease in peripheral B cell abundance and their more differentiated phenotype have been confirmed both in breast cancer patients with germline pathogenic variants in BRCA1 (gpath( BRCA1 )) and in patients living with Lynch syndrome (LS). Pre-cancer women with gpath( BRCA1 ) exhibited an activated phenotype of multiple immune cell lineages, similar to those with manifest disease. In LS, B cell phenotypes exhibited the largest changes in response to cancer eradication, while increased peripheral IL-6 levels was detected even in presymptomatic individuals with LS. Conclusions HCPS-specific differences in the phenotype of the systemic immune system might be leveraged in future risk-reducing strategies.
No takes yet. Share an insight, caveat, or question.
Kelemen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: